| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ACTIVEFINE Stock Overview
Active Fine Chemicals Limited produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh.
Active Fine Chemicals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳19.60 |
| 52 Week High | ৳34.10 |
| 52 Week Low | ৳18.90 |
| Beta | 0.11 |
| 1 Month Change | -10.09% |
| 3 Month Change | -13.27% |
| 1 Year Change | -18.67% |
| 3 Year Change | -19.34% |
| 5 Year Change | -39.00% |
| Change since IPO | -30.30% |
Recent News & Updates
Shareholder Returns
| ACTIVEFINE | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -0.5% | 4.6% | 5.0% |
| 1Y | -18.7% | -0.5% | -8.9% |
Return vs Industry: ACTIVEFINE underperformed the BD Pharmaceuticals industry which returned -0.5% over the past year.
Return vs Market: ACTIVEFINE underperformed the BD Market which returned -8.9% over the past year.
Price Volatility
| ACTIVEFINE volatility | |
|---|---|
| ACTIVEFINE Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BD Market | 6.7% |
| 10% least volatile stocks in BD Market | 2.6% |
Stable Share Price: ACTIVEFINE is not significantly more volatile than the rest of BD stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ACTIVEFINE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | S. M. Rahman | https://www.afchem.com |
Active Fine Chemicals Limited produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh. The company’s APIs include azithromycin dihydrate, erythromycin ethyl succinate, and erythromycin stearate for macrolide-antibiotics; esomeprazole magnesium trihydrates and pellets for anti-ulcerant; fluconazoles for anti-fungal; atorvastatin and rosuvastatin calcium for lipid-lowering; cetirizine and fexofenadine hydrochlorides, desloratadines, and ebastine for anti-histamine; and ciprofloxacin hydrochloride for anti-bacterial therapeutics. It also offers cefixime trihydrates and cefuroxime axetil for cephalosporin-antibiotics; metformin hydrochloride, sitagliptin phosphate monohydrate, vildagliptin, linagliptin, gliclizide, and glimepiride for anti-diabetic; pregabalin for anti-epileptic; paracetamol for analgesic and antipyrotic; losartan potassium and amlodipine besylate for anti-hypertensive; calcium orotate for use in calcium-supplement; sofosbuvir for anti-hepatitis-C; etoricoxib and ketorolac tromethamine for NSAID; and ticagrelor and amlodipine besylate for anti-platelet therapeutic areas, as well as solvents and solid reagents.
Active Fine Chemicals Fundamentals Summary
| ACTIVEFINE fundamental statistics | |
|---|---|
| Market Cap | ৳4.70b |
| Earnings (TTM) | ৳54.82m |
| Revenue (TTM) | ৳1.70b |
85.8x
P/E Ratio2.8x
P/S RatioIs ACTIVEFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTIVEFINE income statement (TTM) | |
|---|---|
| Revenue | ৳1.70b |
| Cost of Revenue | ৳1.32b |
| Gross Profit | ৳379.94m |
| Other Expenses | ৳325.11m |
| Earnings | ৳54.82m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 22.36% |
| Net Profit Margin | 3.23% |
| Debt/Equity Ratio | 57.8% |
How did ACTIVEFINE perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield22%
Payout RatioValuation
Is ACTIVEFINE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACTIVEFINE?
Other financial metrics that can be useful for relative valuation.
| What is ACTIVEFINE's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | ৳4.70b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.2x |
| Enterprise Value/EBITDA | 6.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does ACTIVEFINE's PE Ratio compare to its peers?
| ACTIVEFINE PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 38.5x | ||
ORIONINFU Orion Infusion | 78.1x | n/a | ৳2.7b |
SILVAPHL Silva Pharmaceuticals | 26.8x | n/a | ৳3.2b |
ADVENT Advent Pharma | 20.4x | n/a | ৳2.2b |
SILCOPHL Silco Pharmaceuticals | 32.1x | n/a | ৳2.7b |
ACTIVEFINE Active Fine Chemicals | 85.8x | n/a | ৳4.7b |
Price-To-Earnings vs Peers: ACTIVEFINE is expensive based on its Price-To-Earnings Ratio (85.8x) compared to the peer average (38.5x).
Price to Earnings Ratio vs Industry
How does ACTIVEFINE's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ACTIVEFINE is expensive based on its Price-To-Earnings Ratio (85.8x) compared to the BD Pharmaceuticals industry average (22.4x)
Price to Earnings Ratio vs Fair Ratio
What is ACTIVEFINE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 85.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ACTIVEFINE's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ACTIVEFINE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ACTIVEFINE (BDT19.6) is trading above our estimate of fair value (BDT0.57)
Significantly Below Fair Value: ACTIVEFINE is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Active Fine Chemicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Active Fine Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of ACTIVEFINE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
Past Performance
How has Active Fine Chemicals performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-39.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACTIVEFINE has high quality earnings.
Growing Profit Margin: ACTIVEFINE became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ACTIVEFINE's earnings have declined by 39.6% per year over the past 5 years.
Accelerating Growth: ACTIVEFINE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ACTIVEFINE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.9%).
Return on Equity
High ROE: ACTIVEFINE's Return on Equity (1%) is considered low.
Discover strong past performing companies
Financial Health
How is Active Fine Chemicals's financial position?
Financial Health Score
2/6Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: ACTIVEFINE's short term assets (BDT4.6B) exceed its short term liabilities (BDT3.4B).
Long Term Liabilities: ACTIVEFINE's short term assets (BDT4.6B) exceed its long term liabilities (BDT260.7M).
Debt to Equity History and Analysis
Debt Level: ACTIVEFINE's net debt to equity ratio (46.6%) is considered high.
Reducing Debt: ACTIVEFINE's debt to equity ratio has increased from 21.5% to 57.8% over the past 5 years.
Debt Coverage: ACTIVEFINE's debt is not well covered by operating cash flow (3.6%).
Interest Coverage: ACTIVEFINE's interest payments on its debt are not well covered by EBIT (0.3x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Active Fine Chemicals's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
0.26%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ACTIVEFINE's dividend (0.26%) isn’t notable compared to the bottom 25% of dividend payers in the BD market (1.2%).
High Dividend: ACTIVEFINE's dividend (0.26%) is low compared to the top 25% of dividend payers in the BD market (3.75%).
Stability and Growth of Payments
Stable Dividend: ACTIVEFINE is not paying a notable dividend for the BD market, therefore no need to check if payments are stable.
Growing Dividend: ACTIVEFINE is not paying a notable dividend for the BD market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: ACTIVEFINE is not paying a notable dividend for the BD market.
Cash Payout to Shareholders
Cash Flow Coverage: ACTIVEFINE is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
10.9yrs
Average board tenure
CEO
S. M. Rahman (43 yo)
no data
Tenure
৳300,000
Compensation
Mr. S. M. Saifur Rahman serves as Managing Director and Chief Scientist of Active Fine Chemicals Ltd. Mr. Rahman has been a Director of Active Fine Chemicals Ltd. since December 1, 2004.He serves as a Dir...
Board Members
Experienced Board: ACTIVEFINE's board of directors are seasoned and experienced ( 10.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Active Fine Chemicals Limited's employee growth, exchange listings and data sources
Key Information
- Name: Active Fine Chemicals Limited
- Ticker: ACTIVEFINE
- Exchange: DSE
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ৳4.703b
- Shares outstanding: 239.94m
- Website: https://www.afchem.com
Location
- Active Fine Chemicals Limited
- Navana Osman @ Link
- 214/D, Gulshan-Tejgaon Link Road
- Dhaka
- 1208
- Bangladesh
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/07 00:00 |
| End of Day Share Price | 2022/08/07 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.